{"id":11308,"date":"2025-10-03T11:36:08","date_gmt":"2025-10-03T11:36:08","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-survival-cancer-patients\/"},"modified":"2025-10-03T16:07:03","modified_gmt":"2025-10-03T16:07:03","slug":"hypertermia-prezitie-pacientov","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/sk\/hypertermia-prezitie-pacientov\/","title":{"rendered":"Hypertermia a Pre\u017eitie u Onkologick\u00fdch Pacientov: Klinick\u00e9 D\u00f4kazy Ukazuj\u00fa Zv\u00fd\u0161enie Celkov\u00e9ho Pre\u017eitia (OS) o Viac ako 50 %"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Hypertermia a Pre\u017eitie u Onkologick\u00fdch Pacientov: Klinick\u00e9 D\u00f4kazy Ukazuj\u00fa Zv\u00fd\u0161enie Celkov\u00e9ho Pre\u017eitia (OS) o Viac ako 50 %\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrum Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hypertermia, Onkol\u00f3gia, \u0160t\u00fadie F\u00e1zy III, pre\u017eitie, OS, Kompletn\u00e1 Odpove\u010f, CR, Glioblast\u00f3m, rakovina pankreasu, Sark\u00f3m, rakovina kr\u010dka maternice, rakovina prsn\u00edka, E-E-A-T\"\n      \/* ... Schema FAQPage by bol pridan\u00fd samostatne pre sekciu \u010casto Kladen\u00e9 Ot\u00e1zky *\/\n    }\n<\/script><\/p>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorita a Odbornos\u0165 (E-E-A-T): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vyvinuli <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sk\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, a <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sk\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<article>\n<header>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hypertermia a Pre\u017eitie u Onkologick\u00fdch Pacientov: Klinick\u00e9 D\u00f4kazy Ukazuj\u00fa Zv\u00fd\u0161enie Celkov\u00e9ho Pre\u017eitia (OS) o Viac ako 50 % v Ur\u010dit\u00fdch Pr\u00edpadoch<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V boji proti rakovine je kone\u010dn\u00fdm cie\u013eom pred\u013a\u017ei\u0165 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Celkov\u00e9 Pre\u017eitie (Overall Survival, OS) <\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">s minim\u00e1lnou alebo \u017eiadnou dodato\u010dnou toxicitou<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> V\u010faka svojej jedine\u010dnej schopnosti senzibilizova\u0165 n\u00e1dorov\u00e9 bunky na r\u00e1dioterapiu a chemoterapiu, <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hypertermia (HT)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> tento cie\u013e prekonala. \u00dadaje z <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/sk\/hypertermie-studii-fazy-iii\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">randomizovan\u00fdch klinick\u00fdch \u0161t\u00fadi\u00ed F\u00e1zy III (RCT) a meta-anal\u00fdz<\/span><\/span><\/strong> <\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ukazuj\u00fa, \u017ee pridanie Hypertermie ku \u0161tandardn\u00fdm protokolom m\u00f4\u017ee zv\u00fd\u0161i\u0165 <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*Celkov\u00e9 Pre\u017eitie o 20 %, 50 %, a dokonca o viac ako 100 %\\** pri vysoko agres\u00edvnych karcin\u00f3moch. Predstavujeme najpresved\u010divej\u0161ie d\u00f4kazy s priamymi odkazmi na p\u00f4vodn\u00e9 publik\u00e1cie:<\/span><\/span><\/strong><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Zdvojn\u00e1soben\u00e1 Miera Pre\u017eitia po 2 Rokoch: Glioblast\u00f3m Multiforme<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Glioblast\u00f3m Multiforme (GBM) je najagres\u00edvnej\u0161\u00ed mozgov\u00fd n\u00e1dor <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9457811\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. Randomizovan\u00e1 klinick\u00e1 \u0161t\u00fadia F\u00e1zy I\/II<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1] uk\u00e1zala, \u017ee pridanie Hypertermie k brachiterapii, po konven\u010dnej r\u00e1dioterapii, malo dramatick\u00fd dopad na progn\u00f3zu onkologick\u00fdch pacientov, a to * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">zdvojn\u00e1soben\u00edm miery pre\u017eitia po 2 rokoch<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * :<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Onkologick\u00fd Ukazovate\u013e<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0160tandardn\u00e1 Lie\u010dba (Bez HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0160tandardn\u00e1 + Hypertermia (HT)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relat\u00edvny \u00da\u010dinok (%)<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pre\u017eitie &#8211; 2 Roky<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">15 %<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">31 %<\/span><\/span><\/td>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relat\u00edvne Zv\u00fd\u0161enie OS o +107%<\/span><\/span><\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Relat\u00edvne zv\u00fd\u0161enie pre\u017eitia u onkologick\u00fdch pacientov po 2 rokoch o viac ako 100 % je presved\u010div\u00fdm d\u00f4kazom \u00fa\u010dinnosti Hypertermie ako adjuvantnej onkologickej lie\u010dby<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/p>\n<p><a href=\"https:\/\/www.mdpi.com\/2072-6694\/15\/3\/880\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Nov\u0161ie meta-anal\u00fdzy [2]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> potvrdzuj\u00fa podobn\u00e9 pr\u00ednosy Modulovanej RF Hypertermie (mHT) u novo diagnostikovan\u00e9ho ochorenia, s <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">mierou pre\u017eitia po 1 roku 73% v porovnan\u00ed s 37% v kontrolnej skupine<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (recidivuj\u00face ochorenie) (p = 0,0021).<\/span><\/span><\/p>\n<p><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Siln\u00e9 sign\u00e1ly pre\u017eitia z komparat\u00edvnych \u0161t\u00fadi\u00ed, a to aj v n\u00e1ro\u010dnom klinickom kontexte gli\u00f3mov, ospravedl\u0148uj\u00fa zaradenie HT ako indik\u00e1cie \u00darovne 1A do klinick\u00fdch odpor\u00fa\u010dan\u00ed.<\/span><\/span><\/strong><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Pred\u013a\u017een\u00e1 Doba Pre\u017eitia: Zv\u00fd\u0161enie OS o Viac ako 50 % pri Rakovine Pankreasu<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Pankreasu (Pancreatic Carcinoma, PC) m\u00e1 jednu z najhor\u0161\u00edch progn\u00f3z. Konsolidovan\u00e9 klinick\u00e9 d\u00f4kazy ukazuj\u00fa, \u017ee Hypertermia v\u00fdznamne men\u00ed klinick\u00fd priebeh, pri\u010dom konzistentne preukazuje zv\u00fd\u0161enie OS u onkologick\u00fdch pacientov o viac ako 50 %:<\/span><\/span><\/p>\n<ol>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Adjuvantn\u00e1 Randomizovan\u00e1 Klinick\u00e1 \u0160t\u00fadia HEAT (2022)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [3]:* Pri resekabilnom dukt\u00e1lnom adenokarcin\u00f3me pankreasu viedlo pridanie Region\u00e1lnej Hypertermie (RHT) k <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">mieram pre\u017eitia po 5 rokoch 28,4% oproti 18,7%\\* ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">relat\u00edvne zv\u00fd\u0161enie pre\u017eitia o *52%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ).<\/span><\/span><\/strong><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><a href=\"https:\/\/doi.org\/10.1038\/s41598-024-51693-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Komparat\u00edvna Integrat\u00edvna \u0160t\u00fadia (2023)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [4]:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u200b\u200b* Pri metastatickej rakovine pankreasu bola integrat\u00edvna imunomodula\u010dn\u00e1 lie\u010dba (vr\u00e1tane Modulovanej RF Hypertermie mHT) v\u00fdrazne lep\u0161ia ako konven\u010dn\u00e1 chemoterapia.<\/span><\/span>\n<p><figure id=\"attachment_11256\" aria-describedby=\"caption-attachment-11256\" style=\"width: 1010px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-11256 size-full\" src=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg\" alt=\"Rakovina pankreasu - celkov\u00e9 pre\u017eitie OS - porovnanie medzi imunomodula\u010dn\u00fdmi terapiami (IMT) VS chemoterapiou (CT) VS Modulovanou RF Hypertermiou (mHT) + CT\" width=\"1010\" height=\"850\" title=\"\" srcset=\"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT.jpg 1010w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-300x252.jpg 300w, https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/10\/pancreatic-cancer-OS-comparison-IMT-vs-CT-vs-mHT-CT-768x646.jpg 768w\" sizes=\"auto, (max-width: 1010px) 100vw, 1010px\" \/><figcaption id=\"caption-attachment-11256\" class=\"wp-caption-text\">Rakovina pankreasu &#8211; celkov\u00e9 pre\u017eitie OS &#8211; porovnanie medzi imunomodula\u010dn\u00fdmi terapiami (IMT) VS chemoterapiou (CT) VS Modulovanou RF Hypertermiou (mHT) + CT<\/figcaption><\/figure><\/li>\n<li>\u00a0<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ve\u013ek\u00e1 retrospekt\u00edvna, multicentrick\u00e1 observa\u010dn\u00e1 \u0161t\u00fadia<\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37398545\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [5]<\/span><\/span><\/a><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (N=217 pacientov s PC \u0161t\u00e1diom III-IV) porovn\u00e1vala Modulovan\u00fa RF Hypertermiu (mHT) + chemoterapiu CT (preva\u017ene na b\u00e1ze gemcitab\u00ednu) s iba chemoterapiou CT. <\/span><\/span><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Celkov\u00e9 Pre\u017eitie (OS): OS bolo v\u00fdznamne zlep\u0161en\u00e9 (viac ako ZDVOJN\u00c1SOBEN\u00c9) v skupine Modulovanej RF Hypertermie (mHT) (20 mesiacov, oproti 9 mesiacom v skupine CT, P &lt; 0,001). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Pre\u017eitie Bez Progresie (PFS): PFS bolo taktie\u017e v\u00fdznamne zlep\u0161en\u00e9 (7 mesiacov, oproti 5 mesiacom, P &lt; 0,05). <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u25cf Odpove\u010f N\u00e1doru: Pacienti lie\u010den\u00ed lok\u00e1lnou RF Hypertermiou (mHT) mali v\u00fdznamne vy\u0161\u0161iu mieru \u010ciasto\u010dnej Odpovede (PR) (45% oproti 24%, P = 0,0018) a v\u00fdznamne ni\u017e\u0161iu Mieru Progresie (PD) (4% oproti 31%, P &lt; 0,01).<\/span><\/span><\/strong><\/li>\n<\/ol>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Dlhodob\u00e1 Dokument\u00e1cia F\u00e1zy III: Sark\u00f3m M\u00e4kk\u00fdch Tkan\u00edv (EORTC 62961)<\/span><\/span><\/h2>\n<p><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V mnohon\u00e1rodnej randomizovanej klinickej \u0161t\u00fadii F\u00e1zy III (RCT), zlatom \u0161tandarde,<\/span><\/span><\/span><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EORTC 62961\/ESHO 95<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * [5] , <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">u pacientov podstupuj\u00facich NACT (neoadjuvantn\u00fa chemoterapiu) pre sark\u00f3m m\u00e4kk\u00fdch tkan\u00edv (STS), <\/span><\/span><a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9856725\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">bol medi\u00e1n Celkov\u00e9ho Pre\u017eitia (OS) viac ako ZDVOJN\u00c1SOBEN\u00dd<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , s minim\u00e1lnou toxicitou <\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, \u010do viedlo k zaradeniu HT do odpor\u00fa\u010dan\u00ed NCCN a ESMO.<\/span><\/span><\/span><\/strong><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0160t\u00fadia bola iniciovan\u00e1 <\/span><\/span><a href=\"http:\/\/esho.info\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Eur\u00f3pskou Spolo\u010dnos\u0165ou pre Hypertermick\u00fa Onkol\u00f3giu (ESHO)<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> a koordinovan\u00e1 Klinikum der Universit\u00e4t M\u00fcnchen, Nemecko, v spolupr\u00e1ci so Skupinou pre Sark\u00f3m M\u00e4kk\u00fdch Tkan\u00edv a Kost\u00ed (STBSG) pri Eur\u00f3pskej Organiz\u00e1cii pre V\u00fdskum a Lie\u010dbu Rakoviny (EORTC). Z\u00fa\u010dastnen\u00e9 akademick\u00e9 centr\u00e1 boli v Nemecku (6), N\u00f3rsku (1), Rak\u00fasku (1) a USA (1).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dospel\u00ed pacienti (vek \u226518 rokov) s lokalizovan\u00fdm sark\u00f3mom m\u00e4kk\u00fdch tkan\u00edv (n\u00e1dor \u22655 cm, stupe\u0148 2 alebo 3, hlbok\u00fd, pod\u013ea klasifik\u00e1cie Franc\u00fazskej N\u00e1rodnej Feder\u00e1cie Centier pre Kontrolu Rakoviny [FNCLCC]) boli zaraden\u00ed v 9 centr\u00e1ch od j\u00fala 1997 do novembra 2006. Sledovanie bolo ukon\u010den\u00e9 v decembri 2014. <\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pridanie Region\u00e1lnej Hypertermie (RHT) pred\u013a\u017eilo medi\u00e1n pre\u017eitia bez ochorenia zo 17,4 mesiaca na 33,3 mesiaca<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (HR pre lok\u00e1lne alebo vzdialen\u00e9 zlyhanie alebo \u00famrtie, 0,71; 95% IS, 0,55\u20130,93; <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0\u2009= 0,01;\u00a0 <\/span><\/span><\/span><a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Obr\u00e1zok 2B<\/span><\/span><\/span><\/a><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0).<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Pre\u017eitie medzi \u0161tudijn\u00fdmi skupinami bolo v\u00fdznamne zlep\u0161en\u00e9 v skupine NACT plus RHT, s medi\u00e1nom trvania 15,4 roka v porovnan\u00ed s 6,2 roka v skupine iba NACT<\/strong> (HR 0,73; 95% IS, 0,54-0,98;\u00a0<i>P<\/i>\u2009=\u20090,04;\u00a0<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Obr\u00e1zok 2<\/a>C). <\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Miery pre\u017eitia po 5 a 10 rokoch boli 62,7 % (95% IS, 55,2%-70,1%) a 52,6 % (95% IS, 44,7%-60,6%) v skupine NACT plus RHT<\/strong> a 51,3 % (95% IS, 43,7%-59,0%) a 42,7 % (95% IS, 35,0%-50,4%) v skupine iba NACT, v tomto porad\u00ed. Po\u010det pacientov, ktor\u00fdch bolo potrebn\u00e9 lie\u010di\u0165 na dosiahnutie pr\u00ednosu v pre\u017eit\u00ed po 5 a 10 rokoch, bol 8,8 a 10,1, v tomto porad\u00ed. Post-hoc anal\u00fdzy uk\u00e1zali, \u017ee u pacientov s n\u00e1dormi kon\u010dat\u00edn boli miery pre\u017eitia po 5 a 10 rokoch v prospech RHT 75,2 % oproti 60,8 % (absol\u00fatny rozdiel, 14,4 %; 95% IS, 0,0%-29,5%) a 68,3 % oproti 59,2 % (absol\u00fatny rozdiel, 9,1 %; 95% IS, 0%-24,7%). U pacientov s n\u00e1dormi, ktor\u00e9 neboli na kon\u010datin\u00e1ch, boli miery pre\u017eitia po 5 a 10 rokoch v prospech RHT 53,5 % oproti 44 % (absol\u00fatny rozdiel, 9,5 %; 95% IS, 0%-23,8%) a 41,3 % oproti 29,9 % (absol\u00fatny rozdiel, 11,4 %; 95% IS 0%-25,1%) (<a class=\"figure-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#coi170090f2\" data-tab-toggle=\".tab-nav-figure-table\" target=\"_blank\" rel=\"noopener\">Obr\u00e1zok 2<\/a>D). S\u00fahrn v\u00fdsledkov lie\u010dby je uveden\u00fd v eTabu\u013eke 1 v\u00a0<a class=\"supplement-link section-jump-link\" href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2672386#note-COI170090-1\" data-tab-toggle=\".tab-nav-supplemental\" target=\"_blank\" rel=\"noopener\">Doplnku 2<\/a>.<\/span><\/span><\/span><\/p>\n<p><span dir=\"auto\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pre\u017eitie bolo v\u00fdznamne zlep\u0161en\u00e9 pridan\u00edm region\u00e1lnej hypertermie k neoadjuvantnej chemoterapii, s absol\u00fatnym rozdielom 11,4 % po 5 rokoch a 9,9 % po 10 rokoch,<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> v porovnan\u00ed so samotnou neoadjuvantnou chemoterapiou.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. D\u00f4kazy \u00darovne 1A z Klinick\u00fdch \u0160t\u00fadi\u00ed F\u00e1zy III: Zlep\u0161enie Kompletnej Odpovede (CR) a Pre\u017eitia (OS)<\/span><\/span><\/h2>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/17881144\/\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Kr\u010dka Maternice (12-ro\u010dn\u00e9 sledovanie)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [7]:* Holandsk\u00e1 Klinick\u00e1 \u0160t\u00fadia Hlbokej Hypertermie (F\u00e1za III), aktualizovan\u00e1 po 12 rokoch sledovania, uk\u00e1zala ve\u013ek\u00e9 zlep\u0161enie v Celkovom Pre\u017eit\u00ed (OS): <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">37% v skupine RT+HT oproti 20% v skupine iba RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Recidivuj\u00faca Rakovina Prsn\u00edka (Hrudn\u00e1 Stena)<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* Meta-anal\u00fdza<a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301615271994\" target=\"_blank\" rel=\"noopener\">[8]<\/a> uk\u00e1zala <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">relat\u00edvne zv\u00fd\u0161enie miery Kompletnej Odpovede (CR) o +58% pridan\u00edm HT k re-o\u017earovaniu. <\/span><\/span><\/strong>\u00a0<span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V \u0161t\u00fadi\u00e1ch s 2 ramenami bolo <strong>Kompletnej Odpovede (CR) dosiahnut\u00e9 u 60,2 %<\/strong> <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">s RT + HT v porovnan\u00ed s 38,1 % s iba RT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0(pomer \u0161anc\u00ed 2,64, 95% interval spo\u013eahlivosti [IS] 1,66\u20134,18, <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001). Pomer riz\u00edk a rozdiel riz\u00edk boli 1,57 (95% IS 1,25\u20131,96,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0&lt;0,0001) a 0,22 (95% IS 0,11\u20130,33,\u00a0 <\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P\u00a0<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> &lt;0,0001), v tomto porad\u00ed.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><a href=\"https:\/\/link.springer.com\/article\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Kone\u010dn\u00edka (Pokro\u010dil\u00e1\/Recidivuj\u00faca)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[9]<\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/strong><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * <\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Po 5 rokoch sledovania boli miery Celkov\u00e9ho Pre\u017eitia (OS) <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">(95,8 oproti 74,5%, <\/span><\/span><\/strong><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,045), Pre\u017eitia Bez Ochorenia (DFS) ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">89,1 oproti 70,4%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,027), Pre\u017eitia Bez Lok\u00e1lnej Recid\u00edvy ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">97,7 oproti 78,7%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,006) a Pre\u017eitia Bez Kolost\u00f3mie ( <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">87,7 oproti 69,0%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , <\/span><\/span><\/span><i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">P<\/span><\/span><\/span><\/i><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u202f= 0,016) boli v\u00fdznamne lep\u0161ie pre skupinu onkologick\u00fdch pacientov s Hypertermiou pridanou k lie\u010dbe.<\/span><\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Hlavy a Krku (HNC)<\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">: <\/span><\/span><\/strong><a href=\"https:\/\/doi.org\/10.7314\/apjcp.2013.14.12.7395\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Randomizovan\u00e9 \u0161t\u00fadie F\u00e1zy III<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> uk\u00e1zali <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">konzistentn\u00e9 zv\u00fd\u0161enie 5-ro\u010dn\u00e9ho OS z 50% na 68,4% (p &lt; 0,005). 5-ro\u010dn\u00e9 Pre\u017eitie Bez Ochorenia (DFS) sa zv\u00fd\u0161ilo z 25,5% na 51,3% (p &lt; 0,005). Miera CR sa taktie\u017e zv\u00fd\u0161ila z 62,8% na 81,6%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . V inej <\/span><\/span><a href=\"https:\/\/journals.lww.com\/cancerjournal\/fulltext\/2010\/06040\/hyperthermia_with_radiation_in_the_treatment_of.16.aspx\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0161t\u00fadii F\u00e1zy III[10] <\/span><\/span><\/a><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">bola Kompletn\u00e1 Odpove\u010f (CR) pozorovan\u00e1 u 42,4 % v skupine iba r\u00e1dioterapie oproti 78,6 % v skupine s HT<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> . Rozdiel bol \u0161tatisticky v\u00fdznamn\u00fd (&lt; 0,05).<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vysoko Rizikov\u00fd Mal\u00edgny Melan\u00f3m (EORTC 18951\/ESHO 1.96)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> :* <\/span><\/span><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/7776772\/\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Klinick\u00e1 \u0161t\u00fadia F\u00e1zy II\/III[11]<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> uk\u00e1zala, \u017ee Region\u00e1lna Hypertermia v kombin\u00e1cii s chemoterapiou v\u00fdznamne zlep\u0161uje Celkov\u00e9 Pre\u017eitie aj u pacientov s pokro\u010dil\u00fdm melan\u00f3mom:<\/span><\/span>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-ro\u010dn\u00e9 Celkov\u00e9 Pre\u017eitie:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Celkov\u00e1 miera bola 19%.<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5-ro\u010dn\u00e9 pre\u017eitie pre pacientov s kompletne kontrolovan\u00fdm ochoren\u00edm:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Zv\u00fd\u0161ilo sa na <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">38%<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> .<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aktu\u00e1rska Lok\u00e1lna Kontrola po 2 Rokoch <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">28% OPROTI <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">46% v skupine s HT <\/span><\/span><\/strong><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">V\u00fdznamn\u00e9 Zlep\u0161enie (p = 0,008)<\/span><\/span><\/strong><\/li>\n<\/ul>\n<\/li>\n<li>\n<section><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Rakovina Mo\u010dov\u00e9ho Mech\u00fara (Ne-svalovo Invaz\u00edvna)<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Rakovina mo\u010dov\u00e9ho mech\u00fara je jednou z indik\u00e1ci\u00ed \u00darovne 1A pre pridanie Hypertermie k onkologickej lie\u010dbe.[12] Hypertermick\u00e1 Intravezik\u00e1lna Chemoterapia (HIVEC) v kombin\u00e1cii s Mitomyc\u00ednom C je zaveden\u00e1 met\u00f3da, ktor\u00e1 preukazuje v\u00fdznamn\u00e9 zlep\u0161enie v miere recid\u00edv:<\/span><\/span><\/p>\n<ul>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Zn\u00ed\u017eenie Recid\u00edvy: Pri ne-svalovo invaz\u00edvnej rakovine mo\u010dov\u00e9ho mech\u00fara so stredn\u00fdm a vysok\u00fdm rizikom sa HIVEC uk\u00e1zal by\u0165 lep\u0161\u00ed ako \u0161tandardn\u00e9 instil\u00e1cie chemoterapie pri izbovej teplote.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konsolidovan\u00e9 V\u00fdsledky: Meta-anal\u00fdzy a klinick\u00e9 \u0161t\u00fadie (vr\u00e1tane randomizovan\u00fdch \u0161t\u00fadi\u00ed) hl\u00e1sili zn\u00ed\u017eenie rizika recid\u00edvy o viac ako 30 % v porovnan\u00ed so \u0161tandardnou intravezik\u00e1lnou chemoterapiou u pacientov so stredn\u00fdm a vysok\u00fdm rizikom [12]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00da\u010dinnos\u0165 pri Zlyhan\u00ed BCG: HIVEC je d\u00f4le\u017eitou alternat\u00edvou pre pacientov, u ktor\u00fdch \u0161tandardn\u00e1 terapia BCG (Bacillus Calmette-Gu\u00e9rin) zlyhala alebo je kontraindikovan\u00e1, zlep\u0161uj\u00faca Pre\u017eitie Bez Recid\u00edvy (RFS).<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<section>\n<h2><\/h2>\n<\/section>\n<\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">5. Bezpe\u010dnos\u0165 a Priazniv\u00fd Terapeutick\u00fd Index (Toxicita)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">K\u013e\u00fa\u010dov\u00fdm aspektom dokument\u00e1cie F\u00e1zy III je, \u017ee obrovsk\u00fd pr\u00ednos v pre\u017eit\u00ed je dosiahnut\u00fd bez v\u00fdznamn\u00e9ho zv\u00fd\u0161enia z\u00e1va\u017enej toxicity Stup\u0148a 3 alebo 4. Napr\u00edklad meta-anal\u00fdzy o rakovine kr\u010dka maternice nezaznamenali \u017eiadny v\u00fdznamn\u00fd rozdiel v ak\u00fatnej alebo neskorej toxicite (RR 0,99 pre ak\u00fatnu toxicitu, RR 1,01 pre neskor\u00fa toxicitu).<\/span><\/span><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Toto pozorovanie plat\u00ed aj pre in\u00e9 indik\u00e1cie, \u010do posil\u0148uje argument, \u017ee HT pon\u00faka superiorn\u00fd terapeutick\u00fd index, ktor\u00fd umo\u017e\u0148uje pacientom lep\u0161ie tolerova\u0165 zlo\u017eit\u00e9 lie\u010debn\u00e9 re\u017eimy a ma\u0165 zlep\u0161en\u00fa Kvalitu \u017divota z dlhodob\u00e9ho h\u013eadiska.<\/span><\/span><\/p>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Z\u00e1ver: Certifikovan\u00e1 Strat\u00e9gia Pre\u017eitia<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u010ci u\u017e ide o <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">zv\u00fd\u0161enie OS o 52 % (rakovina pankreasu), zv\u00fd\u0161enie o +17 percentu\u00e1lnych bodov po 12 rokoch (rakovina kr\u010dka maternice) alebo Zdvojn\u00e1sobenie doby pre\u017eitia (Glioblast\u00f3m a Sark\u00f3m M\u00e4kk\u00fdch Tkan\u00edv),<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> dokument\u00e1cia z randomizovan\u00fdch \u0161t\u00fadi\u00ed potvrdzuje, \u017ee Hypertermia nie je len adjuvantn\u00e1 lie\u010dba, ale k\u013e\u00fa\u010dov\u00e1 zlo\u017eka, ktor\u00e1 pozit\u00edvne men\u00ed dr\u00e1hu <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Celkov\u00e9ho Pre\u017eitia<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> pre onkologick\u00fdch pacientov.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ak je va\u0161\u00edm cie\u013eom maximalizova\u0165 Celkov\u00e9 Pre\u017eitie, integr\u00e1cia Hypertermie do \u0161tandardn\u00e9ho protokolu je vedecky overen\u00fdm rozhodnut\u00edm s v\u00fdsledkami preukazuj\u00facimi relat\u00edvne zv\u00fd\u0161enie o viac ako 50 % v ur\u010dit\u00fdch indik\u00e1ci\u00e1ch.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Z\u00e1ruka E-E-A-T:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Tento obsah je zalo\u017een\u00fd na konsolidovan\u00fdch \u00fadajoch z randomizovan\u00fdch klinick\u00fdch \u0161t\u00fadi\u00ed F\u00e1zy III a prospekt\u00edvnych randomizovan\u00fdch \u0161t\u00fadi\u00ed, publikovan\u00fdch v prest\u00ed\u017enych lek\u00e1rskych \u010dasopisoch. Kompletn\u00e9 referencie s\u00fa integrovan\u00e9 s odkazmi na p\u00f4vodn\u00e9 publik\u00e1cie.<\/span><\/span><\/small><\/p>\n<\/footer>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Referencie:<\/span><\/span><\/p>\n<ol>\n<li>Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH. Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +\/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Phys. 1998 Jan 15;40(2):287-95. doi: 10.1016\/s0360-3016(97)00731-1. PMID: 9457811.<\/li>\n<li>Szasz, A.M.; Arrojo Alvarez, E.E.; Fiorentini, G.; Herold, M.; Herold, Z.; Sarti, D.; Dank, M. Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas.\u00a0<em>Cancers<\/em>\u00a0<b>2023<\/b>,\u00a0<em>15<\/em>, 880. https:\/\/doi.org\/10.3390\/cancers15030880<\/li>\n<li><span class=\"hlFld-ContribAuthor\"><a title=\"articles by this author\" href=\"https:\/\/ascopubs.org\/action\/doSearch?ContribAuthorRaw=Issels%2C+Rolf+D\" target=\"_blank\" rel=\"noopener\">Rolf D. Issels et al.<\/a><\/span>Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomized clinical trial.. <i>J Clin Oncol<\/i>\u00a0<b>41<\/b>, e16316-e16316(2023).DOI:<a title=\"Link to DOI\" href=\"https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e16316\" target=\"_blank\" rel=\"noopener\">10.1200\/JCO.2023.41.16_suppl.e16316\u00a0<\/a><\/li>\n<li><span style=\"font-size: 16px;\">Kleef, R., Dank, M., Herold, M. <i>et al.<\/i>\u00a0Author Correction: Comparison of the effectiveness of integrative immunomodulatory treatments and conventional therapies on the survival of selected gastrointestinal cancer patients.\u00a0<i>Sci Rep<\/i>\u00a0<b>14<\/b>, 1129 (2024).\u00a0<\/span><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Issels RD <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Lindner LH\u00a0 <\/span><\/span><\/span><span class=\"al-author-delim\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">,<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0Verweij J et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes in patients with high-risk localized soft tissue sarcoma\u00a0 <\/span><\/span><\/span><span class=\"subtitle\"><span class=\"colon-for-citation-subtitle\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">:<\/span><\/span><\/span><\/span><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u00a0the EORTC 62961-ESHO 95 randomized clinical trial.\u00a0 <\/span><\/span><\/span><\/span><em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">JAMA Oncol.<\/span><\/span><\/span><\/em><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> 2018 ;4(4):483\u2013492. doi:10.1001\/jamaoncol.2017.4996\u00a0<\/span><\/span><\/span><\/li>\n<li>Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, W\u00e1rl\u00e1m-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J. Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial. Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. doi: 10.1016\/j.ijrobp.2007.07.2348. Epub 2007 Sep 19. PMID: 17881144.<\/li>\n<li><span class=\"title-text\"><span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Niloy R.<\/span>\u00a0<span class=\"text surname\">Datta<\/span> MD, Emsad Puric MD,<\/span><\/span><\/span>\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Dirk<\/span>\u00a0<span class=\"text surname\">Klingbiel<\/span> PhD\u00a0<\/span><\/span><\/span>, Silvia Gomez MD,\u00a0<span class=\"anchor-text-container\"><span class=\"anchor-text\"><span class=\"react-xocs-alternative-link\"><span class=\"given-name\">Stephan<\/span>\u00a0<span class=\"text surname\">Bodis<\/span> MD ,<\/span><\/span><\/span>Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis<\/span>\n<div id=\"banner\" class=\"Banner\"><\/div>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Huilgol, Nagraj G.; Gupta, Sapna; C. R., Sridhar. Hyperthermia with radiation in the treatment of locally advanced head and neck cancer .A report of randomized trial. <span class=\"ej-journal-name\">Journal of Cancer Research and Therapeutics <\/span><span id=\"ej-journal-date-volume-issue-pg\"><a href=\"https:\/\/journals.lww.com\/cancerjournal\/toc\/2010\/06040\" target=\"_blank\" rel=\"noopener\">6(4):p 492-496, Oct\u2013Dec 2010.<\/a><\/span><span class=\"ej-journal-doi\">DOI:\u00a0<\/span>10.4103\/0973-1482.77101<\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">[ Abstract ] Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O, Bentzen SM. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. The Lancet. 1995 Mar 4;345(8949):540-3. doi: 10.1016\/s0140-6736(95)90463-8. PMID: 7776772.<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Angulo JC, Alvarez-Ossorio JL, Dominguez-Escrig JL, Moyano JL, Sousa A, Fernandez JM, Gomez-Veiga F, Unda M, Carballido J, Carrero V, Fernandez-Aparicio T, Garcia de Jalon AA, Solsona E, Inman B, Palou JC. Non-muscle-invasive Bladder Cancer: Results of the HIVEC-1 Trial. Eur Urol Oncol. 2023 Feb;6(1):58-66. doi: 10.1016\/j.euo.2022.10.008. Epub 2022 Nov 23. PMID:36435738.<\/span><\/span><\/span><\/span><\/li>\n<\/ol>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autorita a Odbornos\u0165 (E-E-A-T): Vyvinuli Dr. Veronica Iatan , MD, a Cristian Gologan M.Sc , Andromedichyperthermia Hypertermia a Pre\u017eitie u Onkologick\u00fdch Pacientov: Klinick\u00e9 D\u00f4kazy Ukazuj\u00fa Zv\u00fd\u0161enie Celkov\u00e9ho Pre\u017eitia (OS) o Viac ako 50 % v Ur\u010dit\u00fdch Pr\u00edpadoch V boji proti rakovine je kone\u010dn\u00fdm cie\u013eom pred\u013a\u017ei\u0165 Celkov\u00e9 Pre\u017eitie (Overall Survival, OS) s minim\u00e1lnou alebo \u017eiadnou dodato\u010dnou&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[179,999,30],"tags":[624,766,758,761,765,628,760,763,762,764,767,759,1006],"class_list":["post-11308","post","type-post","status-publish","format-standard","hentry","category-news-sk","category-studii-clinice-sk","category-uncategorized-sk","tag-cr-sk","tag-glioblastom-sk","tag-hypertermia","tag-kompletna-odpoved","tag-onkologia-sk","tag-os-sk","tag-prezitie","tag-rakovina-krcka-maternice","tag-rakovina-pankreasu","tag-rakovina-prsnika","tag-sarkom-sk","tag-studie-fazy-iii","tag-studii-faza-iii-sk"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/posts\/11308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/comments?post=11308"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/posts\/11308\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/media?parent=11308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/categories?post=11308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/sk\/wp-json\/wp\/v2\/tags?post=11308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}